VTUS - Whoa...how do you see this moving forward Norm?
Plunged to a one-year low of 85 cents on Monday after the company agreed to merge with Assembly Pharmaceuticals in an all-stock transaction.
The combined company will be known as Aseembly Biosciences and will trade on the NASDAQ under the ticker ASMB. This new company will focus on the development of Assembly's small molecules to treat, and possibly cure, the hepatitis B virus infection.
Ventrus will issue approximately 23 million shares of common stock to Assembly's stockholders under the deal. At the time of issuance, 20,322,760 shares will be issued common stock and 2,829,740 shares will be shares underlying stock options of Assembly. The companies expect the merger to be completed by July 10, 2014. The deal is subject to approval by Ventrus stockholders.
News 
Market Data 
Discover 
